Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC: Effects on Peripheral Lymphocyte Subsets
ChiCTR2200055581Phase 4Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Peripheral blood lymphocyte subsets. Started Jan 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200055581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055581.